TDOC | Ticker Profile - Titan Protect

TDOC

Teladoc Health, Inc.

Healthcare · Health Information Services · NYQ

$7.05

Data: 2026-05-28

✓ ETHICAL PASS

Unknown MOAT

HIGH

Data Confidence: 85.7%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$1.2B

Total market value of the company

Trailing P/E

N/A

Forward P/E

-10.18

Based on estimated future earnings — lower means cheaper

Rev Growth

-2.5%

Year-over-year revenue change

Profit Margin

-6.8%

How much profit the company keeps from each dollar of revenue

ROE

-12.4%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$7.00

-1% from current price — median analyst estimate

Recommendation

BUY

Consensus view from 21 analysts covering this stock

About Teladoc Health, Inc.

Teladoc Health, Inc. provides virtual healthcare services worldwide. It operates through Teladoc Health Integrated Care and BetterHelp segments. The Integrated Care segment offers virtual medical services, including general medical, expert medical services, specialty medical, chronic condition management, and mental health services, as well as technologies and enterprise telehealth solutions for hospitals and health systems. Its BetterHelp segment operates a mental health platform that provides online counselling and therapy services through websites, mobile applications, phones, and text-based interactions by its licensed clinicians. The company offers its products and services under the Teladoc and BetterHelp brands. It serves employers, health plans, hospitals and health systems, insurance companies, and financial services companies, as well as individual members. The company was formerly known as Teladoc, Inc. and changed its name to Teladoc Health, Inc. in August 2018. Teladoc Health, Inc. was incorporated in 2002 and is headquartered in New York, New York.

https://www.teladochealth.com

Country: United States Employees: 4,648 Industry: Health Information Services

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% N/A

Debt must be below 33% of total assets

Cash Ratio

0.0% N/A

Interest-bearing cash below 33% of assets

Receivables

0.0% N/A

Receivables below 49% of assets

Revenue Purity

0.0% PASS

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

ACCUMULATION

Smart money appears to be building positions quietly

Sharpe Ratio

-0.038

Returns do not compensate for the risk — negative edge

Kelly Fraction

-0.0201

No positive edge detected — the data suggests staying out

Calmar Ratio

-0.262

Drawdown risk outweighs the returns — higher risk profile

Annual Return

-18.0%

Historical annualised return based on price data

Max Drawdown

-68.8%

Largest peak-to-trough decline — the worst it has been

HMM State

BULL

Statistical model sees bullish momentum

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

2.08

Significantly more volatile than the market

52W High

$9.77

28% below the year high

52W Low

$4.40

60% above the year low

Avg Volume

4,891,749

Average daily shares traded — higher means easier to buy and sell

Short Ratio

4.8

Days it would take all short sellers to cover — higher means more crowded

Short % Float

14.8%

Elevated short interest — bears are positioned against this

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-0.97

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

77.68

Heavy leverage — higher financial risk if revenues decline

Current Ratio

2.80

Strong balance sheet — comfortably covers short-term obligations

Quick Ratio

2.40

Like current ratio but excludes inventory — stricter test

Gross Margin

69.3%

Revenue left after cost of goods — higher means pricing power

Operating Margin

-7.9%

Profit from core operations before interest and tax

Free Cash Flow

$208M

Positive — the business generates more cash than it spends

Revenue (TTM)

$2.5B

Total revenue over the last 12 months

Net Income

$-171,147,008

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$10.00

Target Median

$7.00

Target Low

$5.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-28

Before you go